Gilead Sciences Signs Deal With US Government to Lower Drug Costs

MT Newswires Live12-20 04:09

Gilead Sciences (GILD) said Friday it signed a three-year agreement with the US government aiming to reduce drug costs for Americans.

The agreement includes discounts on certain existing medicines within the Medicaid program and a direct-to-patient program offering discounts to Gilead's Hepatitis C treatment Epclusa, the company said.

Gilead said it also entered into an agreement with the Department of Commerce to be exempt from Section 232 pharmaceutical tariffs for three years, provided Gilead further invests in manufacturing in the country.

Based on the agreement terms, the company said it expects the financial impact to be "manageable" in 2026 and beyond.

Additional terms of the agreement with the government remain confidential, Gilead said.

Price: 125.35, Change: +3.88, Percent Change: +3.19

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment